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Hyperbilirubinemia is so common in newborns as to be termed physiological. The most common 
bacteria involved in early-onset neonatal sepsis are Streptococcus agalactiae, commonly called Group B 
Streptococcus (GBS). Whilst previous studies show bilirubin has antioxidant properties and is beneficial 
in endotoxic shock, little thought has been given to whether bilirubin might have antibacterial 
properties. In this study, we performed a transcriptomic and proteomic assessment of GBS cultured in 
the presence/absence of bilirubin. Our analysis revealed that increasing levels of bilirubin (>100 µmol/L) 
negatively correlated with GBS growth (18% reduction from 0–400 µmol/L on plate model, p < 0.001; 
33% reduction from 0–100 µmol/L in liquid model, p = 0.02). Transcriptome analysis demonstrated 19 
differentially expressed genes, almost exclusively up-regulated in the presence of bilirubin. Proteomic 
analysis identified 12 differentially expressed proteins, half over-expressed in the presence of bilirubin. 
Functional analysis using Gene Ontology and KEGG pathways18 revealed a differential expression 
of genes involved in transport and carbohydrate metabolism, suggesting bilirubin may impact on 
substrate utilisation. The data improve our understanding of the mechanisms modulating GBS survival 
in neonatal hyperbilirubinemia and suggest physiological jaundice may have an evolutionary role in 
protection against early-onset neonatal sepsis.
Jaundice is an extremely common finding in newborn infants after the first 24 hours, being present in between 
60% of term and 80% of preterm infants1. Physiological jaundice is due to both an increase in the production of 
bilirubin, principally by haemolysis of red blood cells, and a reduction in the conjugation of bilirubin by the liver 
enzyme uridine diphosphate glucuronyl transferase2. Generally, physiological jaundice is transient and dimin-
ishes over the first week of life. In breastfed infants in particular, persistent jaundice can be found in 10% of 
infants at 1 month1.
In the majority of infants who develop jaundice it will resolve spontaneously with no ill effects; however, a 
rare few will develop significant complications of bilirubin encephalopathy. Acute bilirubin encephalopathy can 
present with a variety of clinical features including lethargy, irritability, abnormal muscle tone and, in severe 
cases, seizures and apnoea. Chronic bilirubin encephalopathy results in the long-term sequelae of choreoathetoid 
cerebral palsy and sensorineural deafness1. These detrimental effects of hyperbilirubinemia raise the possibility of 
an opposing evolutionary advantage in the first week of life, however little work has been done exploring possible 
benefits. Clinical tolerance of hyperbilirubinaemia is generally low because of the concern regarding encephalop-
athy and kernicterus, therefore bilirubin levels are not generally allowed to remain high for significant periods. 
Bilirubin levels of >100 µmol/l are not uncommon and they can often reach levels of >300 µmol/l untreated. The 
literature to date discusses only the potential benefit of bilirubin as an anti-oxidant3,4, however a recent paper has 
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shown that the anti-oxidant properties appear to become pro-oxidant above around 100 µmol/l, suggesting a pos-
sible dose-dependent dichotomy of function for hyperbilirubinaemia5. Curiously, the creation of bilirubin from 
biliverdin requires a net input of energy during the reduction of biliverdin to bilirubin by biliverdin reductase4. 
Given that biliverdin would be an adequate end product of heme degradation (which indeed it is in birds, reptiles 
and amphibians), it seems curious that additional energy is used to convert it to potentially toxic bilirubin if it has 
no valuable physiological function4.
Neither the current National Institute for Health and Care Excellence (NICE) guideline, nor the updated 
guideline from the American Academy of Paediatrics discuss any possible benefits of hyperbilirubinemia despite 
their comprehensive reviews of the literature1,6. The implication is that hyperbilirubinemia confers no benefit to 
the infant. Indeed, the NICE guideline makes specific mention of breastfeeding being a factor significantly associ-
ated with hyperbilirubinaemia, with no clear reason yet elucidated. It is clear that the potential benefit of neonatal 
jaundice requires further consideration and scientific exploration.
Neonates are prone to overwhelming bacterial sepsis in the first few days of life, so-called “early-onset” sepsis. 
The most common bacteria involved in early-onset sepsis remains Streptococcus agalactiae, commonly referred to 
as Group B Streptococcus7. It is well recognised that bacterial growth can be detrimentally affected by the presence of 
bile, and indeed bile resistance is a commonly used phenotypic tool in differentiating gastrointestinal organisms8. 
The mechanisms by which bile interferes with bacterial growth are multifactorial, but principally involve damage 
to the cell membrane, with the result being that Gram-negative organisms appear inherently more resistant to bile 
than Gram-positive organisms8.
We hypothesised that hyperbilirubinemia in the early neonatal period may confer an advantage to the host by 
negatively influencing bacterial replication and hence improving host survival from bacterial sepsis. We designed 
an in-vitro study to test this hypothesis utilising organisms derived from neonatal blood cultures.
Methods
Bacterial Isolates. Patient-distinct GBS strains were identified from septic neonates from Aberdeen 
Maternity Hospital, UK between January 2009 and March 2011. Isolates were retrieved from Medical 
Microbiology and classified as per their formal microbiology report identity, generated from VITEK®2 sensi-
tivity analysis (BioMerieux). Since no clinical data was utilised in this study and all work was in-vitro, no ethics 
approval was required.
Bilirubin Impact on Growth and GBS Transcriptome and Proteome Analysis. Bacterial isolates 
were grown on 5% horse blood, Columbia blood agar (CBA) plates, harvested, and re-suspended in nutrient 
broth (Oxoid) to achieve a bacterial concentration of ~103 CFU/ml. 100 µl of each bacterial suspension was then 
plated in triplicate onto CBA plates as well as onto CBA plates which contained defined concentrations of bili-
rubin (Sigma-Aldrich) (0, 25, 50, 100, 200, 300, 400 µmol/l) dissolved in DMSO + 1 M NaOH. CBA plates with 
just solvent vehicle (DMSO + 1 M NaOH) were also included as controls. All bilirubin plates were prepared in 
a darkened environment and immediately covered with aluminium foil to prevent bilirubin degradation. After 
inoculation, the plates were again covered immediately and incubated aerobically in the dark at 37 °C overnight, 
upon which time the total number of colonies on each plate was recorded. Statistical analysis was performed 
using SPSS version 24. Following assessment within the plate model, the impact of bilirubin on GBS growth was 
then assessed within liquid culture. GBS strains were inoculated into liquid media containing fetal bovine serum 
supplemented with horse blood to 5% (v/v) with the addition of bilirubin to a final concentration of 100 μM dis-
solved in vehicle (DMSO and 1 M NaOH). A second liquid media (Solvent Control) containing the vehicle but 
no bilirubin was also used. Liquid culture was also used to assess the impact of bilirubin on GBS physiology. For 
both growth and GBS physiology studies, the GBS inoculation concentration was approximately 8 × 105 CFU/mL 
(colonies harvested into nutrient broth, OD600 adjusted to 0.01, then broth added to media to a final volume 
of 10% v/v). These were incubated at 37 °C on a shaking plate (~140 rpm) for up to 24 hours. Experiments were 
performed in triplicate using 3 independent GBS isolates. The stability of bilirubin was determined in the liquid 
culture model over the study timeframe. Total bilirubin concentrations of (0, 25, 50, 75, 100, 200, 300, 400 µmol/l) 
were assessed in triplicate using the Diazo-bilirubin method9. All liquid culture experimental work was under-
taken in foil wrapped tubes in dim light/dark conditions to minimise photo-oxidation of the bilirubin solution. 
Bilirubin solutions were also freshly prepared immediately prior to each experiment.
RNA extraction and purification. After incubation, bacteria were harvested and total RNA was extracted, 
purified and on-column DNase treated using the QIAgen RNeasy mini prep kit according to the manufacturer’s 
instructions (Qiagen, Valencia, CA, USA). Three independent replicates for each GBS isolate were performed. 
The total RNA was then subjected to a second DNase I treatment with Turbo DNase (Applied Biosystems/
Ambion) and were purified using the Qiagen RNeasy MinElute clean-up kit (Qiagen). RNAs were quantified 
using the NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). RNA quality 
was evaluated on Tapestation 2200 with R6K screentape (Agilent Technologies Inc., Santa Clara, CA, USA), and 
all RNAs samples were deemed high quality (RIN ≥ 9).
Bacterial mRNA Library Preparation and RNA-Seq. Ribosomal RNA (rRNA) was depleted using an 
Epicentre® Ribo-Zero™ rRNA Removal Kit (Bacteria) according to the manufacturer’s instructions (Illumina, 
San Diego, CA, USA). Briefly, samples in Ribo-Zero rRNA removal solution were incubated at 68 °C for 10 min 
followed by a 15 min incubation at room temperature. Samples were incubated with the prepared microsphere 
beads at room temperature for 10 min, followed by 50 °C for 10 min and column filtration. The final purification 
of eluted rRNA-depleted mRNA was performed by ethanol precipitation.
www.nature.com/scientificreports/
3Scientific RepoRts |  (2018) 8:6470  | DOI:10.1038/s41598-018-24811-3
Strand-specific cDNA libraries were generated from rRNA-depleted mRNA samples using Ion Total RNA-seq 
Kit v2 for Ion Proton and Ion Xpress RNA-seq barcodes, following the manufacturer’s instructions (Ion Torrent, 
Thermo Fisher Scientific, Waltham, MA, USA). Barcoded libraries were quantified on the Tapestation 2200 with 
D1000 or HSD1000 screentapes (Agilent Technologies Inc., Santa Clara, CA, USA). Template preparation was 
performed on the Ion Chef and RNA-Seq was performed on the Ion Proton with Proton I chip and 200-bp single 
end reads by the Centre for Genome Enabled Biology and Medicine at the University of Aberdeen (Aberdeen, 
UK). Base calling was performed and fastq files generated using Torrent Suite v 4.2.1.
Read mapping was performed on Galaxy at the high-performance research computing centre at the University 
of Aberdeen. Trim Galore! version 0.4.010 was used to trim sequences with a quality score < 20, and sequences 
<20 bp after trimming were filtered. TopHat2 version 2.0.1011, with minimum and maximum intron size of 20 
and 120, respectively, was used to align the filtered reads to the S. agalactiae 2603 V/R reference genome with 
annotation in gff3 format (Ensembl bacteria build 2512; ftp://ftp.ensemblgenomes.org/pub/bacteria/release-25/). 
Feature counts were performed using HTSeq version 0.6.1p113 with a minimum alignment quality of 20 and reads 
counted if they spanned a particular gene in whole or in part, or if the read spanned a gene exon-exon junction 
(intersection non-empty overlap mode).
Statistical Analysis of RNA-Seq Data. Differential expression was calculated using edgeR version 3.6.814, 
built under R version 3.1.1 and a GLM model with two factors: strain and treatment. Normalisation of read 
counts based on library size was performed within edgeR using TMM method. Dispersion and model fit were 
calculated by edgeR using robust = TRUE15. Gene Ontology enrichment, using Fisher’s exact test, was performed 
with Partek Genome Suite version 6 (Partek Inc, USA) using Gene Ontology annotation for S. agalactiae down-
loaded from www.ebi.ac.uk/GOA. Benjamini and Hochberg false discovery rate16 was used to correct for multiple 
testing (FDR ≤ 0.05).
Proteomics. Preparation of samples for protein extraction. Whole cell protein extracts were prepared 
from three independent cultures of each GBS isolate. The bacterial cells were pelleted from the culture media 
by centrifugation at 2500 × g for 10 min and washed with sterile water, to lyse blood cells, then with sterile PBS. 
Preparation of protein extracts and analysis by 2D gel electrophoresis was undertaken within the University of 
Aberdeen Proteomics facility following protocols described previously17.
Functional/pathways analysis. To gain further insight into the effects of bilirubin on GBS, we performed path-
way enrichment analysis using Partek Pathway in Partek Genomic Suite version 6 using the KEGG database and 
S. agalactiae gene annotation18.
Results
Seven GBS isolates were obtained from the Medical Microbiology laboratory at Aberdeen Royal Infirmary from 
neonatal sepsis cases between January 2009 and March 2011. These isolates were assessed for bacterial growth in 
the presence of varying concentrations of bilirubin (0–400 µmol/l) using a plate-based model to span the clin-
ical range seen in the context of neonatal hyperbilirubinaemia. Bilirubin caused a significant reduction in GBS 
growth at concentrations above 100 µmol/l when compared to growth in the absence of bilirubin (Fig. 1A). In 
order to assess the impact of bilirubin on GBS growth in a more clinically reflective model of EOS, we devised 
a novel liquid culture system to more closely simulate hyperbilirubinaemic blood. We found that the highest 
concentration of bilirubin that achieved acceptable stability over the duration of the experiment (24 hrs) was 
100 µmol/l (Supplementary Fig. 1). Importantly, recent evidence suggests a switch from a potent antioxidant to a 
pro-oxidant function for bilirubin at concentrations around 100 µmol/l5. We therefore assessed the effects of 100 
µmoll/l bilirubin on GBS growth in the liquid-culture model. As with the plate-based model, bilirubin caused 
a significant reduction in GBS growth, compared to vehicle alone. At 24hrs there was a 33% reduction in GBS 
growth (p = 0.02; Fig. 1B).
In order to elucidate the impact of bilirubin on GBS physiology, we performed a whole bacterial transcriptome 
and proteome analysis of GBS isolates grown in the presence or absence of bilirubin. We undertook this analysis 
in combination with gene network pathway analysis to gain a comprehensive picture of the underlying molecular 
mechanisms involved in the response of GBS to bilirubin exposure. We elected to perform these analyses on three 
GBS isolates which were chosen at random from the collection, as there were minimal differences in the growth 
profile between the seven strains based on the plate-model. We performed a comprehensive assessment of the 
effects of 100 µmoll/l bilirubin on the transcriptome and proteome of GBS.
Analysis of gene expression by RNA-seq identified 19 genes that were differentially expressed at 100 µmol/l 
bilirubin concentration when compared with vehicle control (FDR adjusted p ≤ 0.1) (Table 1). The majority of 
genes (18/19) had increased expression levels in the presence of bilirubin. Most of the over-expressed genes were 
involved in hydrolase and transport functions. One of the most significant differentially expressed genes was 
over-expression of sag1901 a glucuronyl hydrolase (unsaturated chondroitin disaccharide hydrolase/unsaturated 
glucuronyl hydrolase (UGL; GH88 family)), which is involved in degrading glycosaminoglycans and sulphated 
substrates. Previous investigations of chitosan, a natural polysaccharide with structural characteristics similar to 
glycosaminoglycans, have shown that it can effectively bind bilirubin in in-vitro models19. It is therefore possible 
that, within our liquid model system, GBS is increasing glucuronyl hydrolase production in response to the pres-
ence of bilirubin as an innate defence mechanism in order to bind the perceived toxin.
Genes encoding transport proteins were also upregulated in the presence of bilirubin. These included sag1925 
and sag1441, which both encode components of ABC transporters involved in the transport of sugars. ABC 
transporters are known to translocate a wide variety of endogenous and exogenous substrates across cell mem-
branes and have previously been linked to protecting cells from bilirubin toxicity20. Up-regulation in the presence 
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of bilirubin could reflect expulsion of toxic bilirubin from bacterial cells, or an increased requirement for sugar 
uptake from the culture medium to compensate for increased metabolic demands.
Furthermore, the transcription of genes encoding carbohydrate transport proteins (sag1898, sag1902, sag1899, 
sag1900, sag1441 and sag1690) were also found to be significantly upregulated. These genes are the five subunits 
and components of the phosphotransferase system: PTS transporter subunits IIA – IID, and IIABC components. 
The PTS transport system is widely spread among bacteria of many different species, and it can be used to trans-
port multiple types of carbohydrates into the cell.
Proteomic assessment of bilirubin impact. Changes in the GBS proteome of the clinical isolates fol-
lowing bilirubin exposure were evaluated. The total cellular fractions of a representative GBS isolate are depicted 
in Fig. 2. Alteration in the abundance of 22 proteins was observed when GBS was exposed to bilirubin when 
compared to solvent control. Fourteen proteins were increased, while 8 were decreased in the presence of bil-
irubin (Fig. 3; Table 2). A subset of 10 proteins that were significantly altered in the presence of bilirubin, with 
significance p < 0.025, were further analysed by MALDI-TOF/TOF MS. In this subset, half were upregulated 
and their identities are given in Table 3. Several of the proteins up-regulated in the presence of bilirubin were 
related to transporters, validating the gene expression changes described previously. Peptide ABC transporter 
ATP-binding, ABC transporter permease and Iron ABC transporter ATP-binding protein. Other up-regulated 
proteins included the enzymes phosphoglycerate kinase and s-ribosylhomocysteinase, and also the regulators and 
molecular chaperones GntR family transcriptional regulator and molecular chaperone GroEL (Table 3). Proteins 
which were down-regulated in the presence of bilirubin were related to regulation, synthesis or enzymatic activities. 
These included single-stranded DNA binding protein, N-acetyl neuramic acid synthetase NeuB, and transketolase, 
ornithine carbamoyltransferase, and dTDP-4-dehydrorhamnose reductase. The functional importance of these 
alterations in the proteome in response to bilirubin was further explored by gene ontology and pathways analyses.
Figure 1. Effect of bilirubin on growth of GBS. (A) Solid media model. Total number of colonies were 
determined following overnight incubation of blood agar plates containing bilirubin at concentrations ranging 
from 0–400 µmol/l bilirubin dissolved in DMSO/1 M NaOH. Results are presented as percentage change in 
growth from 100% on DMSO/1 M NaOH control. N = 7 isolates with experiments repeated in triplicate. Values 
are presented as mean+/− SEM. All values depicted with an asterisk were statically significant (independent 
sample T-test). * = 0.011, ** = 0.024 and *** = <0.001. (B) Liquid culture model. Total number of colonies 
were determined following incubation for up to 24 hrs of Blood/serum containing bilirubin at a concentration 
of 100 µmol/l bilirubin dissolved in DMSO/1 M NaOH or Blood/serum containing vehicle (DMSO/1 M 
NaOH). Results are presented as colony forming units (CFU). N = 3 isolates with experiments repeated in 
triplicate. Values are presented as mean + /− SEM. All values depicted with an asterisk were statically significant 
(independent sample T-test). * = 0.02.
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ID Name
log fold 
change p-value FDR
SAG1901 Glucuronyl hydrolase 1.13 1.29E-07 1.29E-04
SAG1807 Hypothetical protein 1.30 1.35E-07 1.29E-04
SAG1898 PTS system transporter subunit IID 1.87 1.06E-06 5.81E-04
SAG0547 Hypothetical protein −1.32 1.22E-06 5.81E-04
SAG0118 Ribokinase 1.12 2.96E-05 1.13E-02
SAG1902 PTS system transporter subunit IIA 1.34 4.07E-05 1.29E-02
SAG1899 PTS system transporter subunit IIC 1.83 5.82E-05 1.59E-02
SAG0169 Formate acetyltransferase 1.32 1.26E-04 2.46E-02
SAG1350 Surface antigen-like protein 2.02 1.28E-04 2.46E-02
SAG0680 Hypothetical protein 0.41 1.29E-04 2.46E-02
SAG0325 Pyruvate formate-lyase-activating enzyme 1.81 1.91E-04 3.31E-02
SAG1900 PTS system transporter subunit IIB 1.55 2.67E-04 4.02E-02
SAG0795 Hypothetical protein 2.83 2.73E-04 4.02E-02
SAG1925 Sugar ABC transporter ATP-binding protein 2.02 3.37E-04 4.60E-02
SAG1441 Maltose/maltodextrin ABC transporter maltose/maltodextrin-binding protein 2.19 4.69E-04 5.91E-02
SAG1690 PTS system transporter subunit IIABC 2.01 5.22E-04 5.91E-02
SAG2072 Uridine phosphorylase 1.70 5.26E-04 5.91E-02
SAG0331 Formate acetyltransferase 1.65 8.21E-04 8.43E-02
SAG2014 Hypothetical protein 1.17 8.39E-04 8.43E-02
Table 1. S. agalactiae genes differentially expressed in response to bilirubin.
Figure 2. Representative 2D Gel electrophoresis image from single isolate (65Q) incubated in three types of media, in 
triplicate. Samples were incubated for 24 hours at 37 °C in blood serum (media), solvent control (DMSO/1 M NaOH) 
(solvent) or 100 µmol/l bilirubin dissolved in DMSO/1 M NaOH. Total protein from each sample was assessed for 
quality by 1DGE prior to resolution by 2DGE and staining by Coomassie Brilliant Blue. These images were used for 
comparison of protein profiles with and without exposure to bilirubin by Progenesis SameSpots.
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Figure 3. Average normalised spot volumes of GBS 19 Y, 63 L and 65 Q, isolates each in triplicate ± standard 
deviation. ANOVA analysis identified 22 significant spots, 14 were up-regulated in the presence of bilirubin, 
and 8 were down-regulated.
Spot # Fold-change p-value
Significantly higher expression in the presence of bilirubin
1788 1.545 0.002
3282 1.709 0.012
3941 1.403 0.015
2160 1.704 0.02
4397 1.369 0.021
1832 2.67 0.027
2309 1.493 0.032
3647 1.51 0.034
3629 1.944 0.037
1858 2.769 0.038
4461 1.62 0.046
2373 1.207 0.048
Significantly lower expression in the presence of bilirubin
2484 1.223 0.018
3514 1.444 0.023
2724 1.239 0.024
2627 1.341 0.024
3028 1.217 0.032
2194 1.792 0.039
2614 1.316 0.043
2579 1.428 0.047
Table 2. S. agalactiae proteins altered in response to bilirubin.
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Gene ontology analysis was performed on the set of differentially expressed genes obtained from the RNA-seq 
analysis, combined with the genes encoding the proteins identified as differentially expressed in response to 
bilirubin. This combined transcriptome and proteome analysis identified carbohydrate metabolism and trans-
port, including the phosphotransferase system (PTS), as significantly altered in response to bilirubin (Table 4). 
Additionally, nucleotide metabolic processes, essential for cell growth and replication, were significantly altered. 
Interestingly, the biological process involving catabolism of arginine (a precursor of nitric oxide) to ornithine, a 
precursor of polyamines, was significantly altered in response to bilirubin (Table 4). Pathway enrichment analysis 
of S. agalactiae KEGG pathways18 identified galactose metabolism, the PTS system and ABC transporters as sig-
nificantly altered in GBS in response to bilirubin (Fig. 4, Supplementary Table 1). These analyses further suggest 
carbohydrate metabolism and transport as key factors in the response of the pathogen S. agalactiae to bilirubin.
Discussion
We have shown in an in-vitro study utilising neonatally-derived blood culture isolates that bilirubin may have 
antibacterial properties against GBS. We then used a combined transcriptomic/proteomic approach to character-
ise the functional impact of bilirubin exposure on GBS physiology by developing a novel in-vitro culture model 
of hyperbilirubinaemia. In doing so, we have identified particular adaptive responses within GBS, highlighting 
in particular gylycosaminoglycan degradation, ABC transporters, and carbohydrate metabolism and transport. 
These suggest putative mechanisms by which GBS adapts to bilirubin exposure, and offer potential therapeutic 
targets for exploitation in future models of hyperbilirubinaemia and sepsis.
The liquid model has two main benefits over the plate-based model. Firstly, the bacteria and the bilirubin are 
in free suspension which is more reflective of blood. Secondly, the addition of serum adds albumin, an important 
binding agent for bilirubin, more closely reflecting the situation in-vivo. The level of albumin in this model was 
Spot # Protein identity (RefSeq protein ID, RefSeq gene ID)
MUDPIT 
score
Sequence 
coverage (%)
Fold-
change p-value
Significantly higher expression in the presence of bilirubin
1788 ABC transporter permease (WP_000897811, no RefSeq gene ID) 37 5 1.545 0.002
3282 Phosphoglycerate kinase (AAL85687, upp) 79 5 1.709 0.012
3941 S-ribosylhomocysteinase (WP_000159883, luxS) 186 39 1.403 0.015
2160 Molecular chaperone GroEL (WP_002435951, groEL) 105 9 1.704 0.021
4397 GntR family transcriptional regulator (WP_000312253, DX05_05330) 48 29 1.369 0.025
Significantly lower expression in the presence of bilirubin
2484 N-acetyl neuramic acid synthetase NeuB (WP_000262516, neuB) 326 55 1.223 0.018
3514 Single-stranded DNA-binding protein (WP_000609585, ssb1) 194 73 1.444 0.023
2724 dTDP-4-dehydrorhamnose reductase (WP_000600895, rfbD) 244 46 1.239 0.024
2627 Ornithine carbamoyltransferase (WP_000793622, arcB1) 193 42 1.341 0.024
3028 Iron ABC transporter ATP-binding protein (WP_000114500, no RefSeq gene ID) 151 35 1.217 0.032
Table 3. LC-MS identified proteins altered in response to bilirubin. 10 significant proteins from across three 
GBS isolates were selected and identified by LC-MS and MUDPIT database.
GO Category
Enrichment 
p-value
Biological Processes
PTS system 2.42E-04
Carbohydrate phosphorylation 4.97E-02
UMP salvage 4.97E-02
Nucleotide catabolic process 4.97E-02
Arginine catabolic process to ornithine 4.97E-02
Carbohydrate transmembrane transport 5.13E-02
Guanosine tetraphosphate metabolic process 6.57E-02
Molecular Functions
Catalytic activity 1.40E-03
Protein-N(PI)-phosphohistidine-sugar phosphotransferase activity 4.30E-02
Carboxyl- or carbamoyltransferase activity 4.97E-02
Transferase activity, transferring pentosyl groups 6.57E-02
Single-stranded DNA binding 9.70E-02
Table 4. GO enrichment analysis depicting enriched biological processes and molecular functions which are 
altered in response to bilirubin exposure. GO categories enriched for the set of 19 genes differentially expressed 
and 12 genes corresponding to proteins differentially expressed.
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not measured or controlled however, and is something that warrants consideration in future studies, particularly 
with a view to approaching those seen in neonates with sepsis. Albumin is known to bind bilirubin in-vivo, how-
ever albumin levels can vary dramatically in neonates depending on gestational age, nutritional state and other 
physiological parameters.
This study was principally limited by being entirely in-vitro, and on a small number of GBS isolates, never-
theless it demonstrates important proof of concept data supporting the hypothesis that bilirubin may have an 
under-recognised antibacterial role of potential importance in neonatal sepsis. Further validation of the effects 
of hyperbilirubinaemia on GBS growth should now be assessed on a larger collection of GBS strains. A further 
limitation is the lack of information relating to the actual GBS strains used within the study. The strains were 
clinically-derived early-onset sepsis isolates. We accept that further work on GBS at a strain level might prove 
interesting, however this was deliberately a clinically-orientated preliminary study, so used information derived 
and used routinely in clinical practice. The information provided on routine blood culture reports in the health-
care setting, from which these isolates were derived, includes species identity and antibiotic sensitivity profiles 
and does not go to strain level for GBS. This was therefore the level of bacterial information used a baseline in this 
study. Further work is now required to explore this concept in animal models of combined hyperbilirubinaemia 
and sepsis, with a broader range of GBS strains, and with more species of Gram-positive and Gram-negative path-
ogens, before clinical studies can be undertaken. Such clinical studies might feasibly randomise neonates at high 
risk of developing sepsis to high or low tolerance thresholds of hyperbilirubinaemia to look at their subsequent 
rates of sepsis and the resultant course of illness.
Although GBS is responsible for a significant number of early-onset sepsis cases, it is not the only pathogen 
linked with this. Escherichia coli accounts for almost a quarter of early-onset sepsis episodes and is the most com-
mon cause of mortality in this condition21,22. We had previously reported that bilirubin had no effect on bacterial 
growth in Gram-negative E. coli clinical strains when compared to GBS strains23. Other studies indicate that 
bilirubin can actually act as a protectant to E. coli strains whilst being highly toxic towards Gram-positive bacteria 
including Enterococcus faecalis24. The proposed mechanism of protection of E. coli was through neutralisation of 
host ROS production, whilst the toxic impact on the Gram-positive organisms was thought to be caused by the 
lipophilic properties of bilirubin. This highlights the pleotropic effects that small molecules metabolites such as 
bilirubin can have on different bacterial species and reinforces the need to investigate different bacterial groups 
rather than relying on extrapolating previous findings.
Hyperbilirubinemia is a recognised feature of sepsis in neonatal, paediatric and adult populations and indeed 
there is evidence to suggest that haem catabolism is increased in the critically ill with a resultant rise in serum 
bilirubin25. It may be that hyperbilirubinemia in this context reflects an innate immune response rather than an 
epiphenomenon, a concept that warrants further exploration, however we should also remain mindful that the 
level of hyperbilirubinaemia appears itself to be an independent prognostic indicator in severe sepsis26. Other 
investigators have explored the role of bilirubin in endotoxic shock. Lanone et al.27 utilised homozygous jaundice 
Gunn rats (which display elevated plasma bilirubin levels of ~150 µmol/l because of deficient glucuronyl trans-
ferase activity) in addition to Sprague-Dawley rats subjected to exogenous bilirubin administration (5 mg/kg 
over 1 minute then 50 mg/kg/hr over 3 hours), achieving ~80 µmol/l serum bilirubin, to demonstrate that when 
subjected to E. coli lipopolysaccharide (LPS), there was a significant decrease in LPS-stimulated nitric oxide (NO) 
production. This effect was due to an attenuation of inducible NO synthase (NOS2) by the effect of bilirubin 
on NADPH oxidase, which is itself involved in NOS2 induction. The same effect was also witnessed in-vitro. 
Physiologically, the reduction in NO production was apparent in a significantly higher blood pressure in both 
hyperbilirubinaemic rat groups after LPS administration. The possibility of utilising bilirubin as a treatment for 
endotoxic shock was explored by Kadl et al.28 who challenged Balb/C mice with a sub-lethal dose of E. coli LPS 
and either treatment with 40 mg/kg bilirubin or a control infusion. This study showed multiple clinical improve-
ments in the bilirubin treated group where bilirubin seemingly attenuated the endotoxin-induced tissue injury 
Figure 4. KEGG pathways analysis (A) Phosphotransferase system, (B) Galactose Metabolism, (C) Selected 
ABC transporters (KEGG is described in the following paper: Kanehisa, M. & Goto, S. KEGG: Kyoto 
encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).
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and exerted potent anti-oxidant activity through a reduction in the expression of pro-inflammatory genes includ-
ing IL-1β and TNF-α. It may be that induction of hyperbilirubinemia (or in the case of neonatology, tolerance 
of physiological hyperbilirubinemia) could be a valuable therapeutic tool in the treatment of sepsis, affecting the 
proliferation of Gram-positive organisms such as GBS, and with additional benefits in endotoxic shock due to 
Gram-negative sepsis. Furthermore, there is a growing body of evidence linking hyperbilirubinemia with several 
other physiological effects related to cellular pathways and homeostasis29. These include not only antioxidant 
effects but also anti-inflammatory, antiproliferative and immunomodulatory activities. Further exploration of 
the potentially wide-ranging positive role of bilirubin in host physiology is overdue and worthy of targeted study.
In an era where the phototherapy units used to treat neonatal jaundice are predominantly driven by light 
emitting diodes, the complications of hyperthermia and dehydration of the past are largely irrelevant. Use of 
phototherapy may therefore tend towards lower treatment thresholds to prevent the complications of hyperbili-
rubinemia, particularly where no “benefit” from hyperbilirubinaemia is perceived. Further studies are therefore 
needed to investigate whether hyperbilirubinemia may have potential benefits in the context of sepsis and, in view 
of our results, with particular reference to the development and progression of early-onset sepsis and, specifically, 
GBS sepsis in the neonate.
Conclusion
Physiological hyperbilirubinemia may have beneficial effects in reducing the growth of pathogenic Group B 
Streptococci, whilst other evidence suggests that hyperbilirubinemia may be protective in Gram-negative endo-
toxic shock. The role that hyperbilirubinemia plays in protecting infants against sepsis requires further research.
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